[Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020].
Fiche publication
Date publication
novembre 2020
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Andrejak C, Cottin V, Crestani B, Debieuvre D, Gonzalez-Bermejo J, Morelot-Panzini C, Stach B, Uzunhan Y, Maitre B, Raherison C
Lien Pubmed
Résumé
The French-speaking Respiratory Medicine Society (SPLF) proposes a guide for the management of possible respiratory sequelae in patients who have presented with SARS-CoV-2 pneumonia (COVID-19). The proposals are based on known data from previous epidemics, preliminary published data on post COVID-19 follow-up and on expert opinion. The proposals were developed by a group of experts and then submitted, using the Delphi method, to a panel of 22 pulmonologists. Seventeen proposals were validated ranging from additional examinations after the minimum assessment proposed in the SPLF monitoring guide, to inhaled or systemic corticosteroid therapy and antifibrotic agents. These proposals may evolve over time as knowledge accumulates. This guide emphasizes the importance of multidisciplinary discussion.
Mots clés
COVID-19, Fibrose, Fibrosis, Interstitial lung disease, Pneumonia, Pneumonie, Pneumopathie interstitielle diffuse, SARS-CoV-2, Sequelae, Séquelles
Référence
Rev Mal Respir. 2020 Nov 27;: